Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 21, 2017 16:01 ET | Source: Trevena Inc.

Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

KING OF PRUSSIA, Pa., July 21, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved,...
July 20, 2017 09:00 ET | Source: Trevena Inc.

Trevena To Host 2017 Analyst Day and Announce Results of ATHENA Open Label Safety Study of OLINVO

– Company now plans to submit its New Drug Application for OLINVOTM (oliceridine injection) in September or October 2017 – – Topline results from ATHENA safety study further support potential value...
July 12, 2017 16:30 ET | Source: Trevena Inc.

Trevena to Host Analyst Day on July 20, 2017

KING OF PRUSSIA, Pa., July 12, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host an Analyst Day on Thursday, July 20, 2017, in New York City. Presentations will...
June 20, 2017 16:01 ET | Source: Trevena Inc.

Trevena Attends National Institutes of Health Meeting to Discuss Development of Novel, Improved Pain Medications

KING OF PRUSSIA, Pa., June 20, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced its recent participation in the “Cutting Edge Science Meeting Series to End the Opioid Crisis:...
June 02, 2017 07:00 ET | Source: Trevena Inc.

Trevena to Present at Investor Conferences in June

KING OF PRUSSIA, Pa., June 02, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be attending the following investor conferences in June: Jefferies 2017 Global...
May 31, 2017 16:01 ET | Source: Trevena Inc.

Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

KING OF PRUSSIA, Pa., May 31, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved,...
May 17, 2017 07:00 ET | Source: Trevena Inc.

Trevena Announces Presentations During the 36th Annual Scientific Meeting of the American Pain Society

– Results presented from the successful APOLLO-1 Phase 3 pivotal efficacy study of OLINVOTM (oliceridine injection) in moderate-to-severe acute pain – – New preclinical research highlights the...
May 04, 2017 07:00 ET | Source: Trevena Inc.

Trevena Reports First Quarter 2017 Financial Results and Provides Corporate Update

– Successfully completed two positive Phase 3 pivotal efficacy studies of OLINVO™ (oliceridine injection) –– OLINVO program on track for NDA submission in fourth quarter of 2017 –– Clinical...
April 26, 2017 18:08 ET | Source: Trevena Inc.

Trevena to Present at the Deutsche Bank Securities 42nd Annual Healthcare Conference

KING OF PRUSSIA, Pa., April 26, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the 42nd Annual Healthcare Conference hosted by Deutsche Bank...
April 06, 2017 07:00 ET | Source: Trevena Inc.

Trevena Announces Presentations at the 42nd Annual Regional Anesthesiology and Acute Pain Medicine Meeting

KING OF PRUSSIA, Pa., April 06, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced the first scientific presentation of positive results from two Phase 3 pivotal efficacy studies...